Upton D Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3509426/publications.pdf

Version: 2024-02-01

94 papers

3,108 citations

236925 25 h-index 55 g-index

95 all docs 95 docs citations 95 times ranked 3740 citing authors

#	Article	IF	CITATIONS
1	International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation, 2010, 89, 779-795.	1.0	898
2	The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation. Pediatric Infectious Disease Journal, 2004, 23, 806-814.	2.0	208
3	Postâ€transplant lymphoproliferative disorders, Epsteinâ€Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13652.	1.6	206
4	Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplantation, 2013, 19, 798-825.	2.4	143
5	LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION IN CHILDREN. Transplantation, 1999, 67, 990-998.	1.0	108
6	Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatric Transplantation, 2005, 9, 450-455.	1.0	98
7	A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder. Transplantation, 2006, 81, 856-861.	1.0	86
8	Effect of Oximetry on Hospitalization in Bronchiolitis. JAMA - Journal of the American Medical Association, 2014, 312, 712.	7.4	85
9	Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: A Canadian multi-centre experience. Pediatric Transplantation, 2001, 5, 198-203.	1.0	81
10	Adenoviral Infections in Pediatric Transplant Recipients. Pediatric Infectious Disease Journal, 2006, 25, 815-818.	2.0	76
11	Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation. Medical Decision Making, 2008, 28, 471-480.	2.4	71
12	Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 648-657.	0.6	70
13	Utility of Semiquantitative Polymerase Chain Reaction for Epsteinâ€Barr Virus to Measure Virus Load in Pediatric Organ Transplant Recipients with and without Posttransplant Lymphoproliferative Disease. Clinical Infectious Diseases, 2001, 33, 145-150.	5 . 8	64
14	Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. Pediatric Transplantation, 2019, 23, e13571.	1.0	59
15	Guidelines for the Prevention and Management of Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> : A Perspective for Canadian Health Care Practitioners. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 4C-24C.	1.9	47
16	Pandemic H1N1 influenza A infection and (atypical) HUSâ€"more than just another trigger?. Pediatric Nephrology, 2011, 26, 3-5.	1.7	46
17	Seven-Valent Pneumococcal Conjugate Vaccine in Pediatric Solid Organ Transplant Recipients. Pediatric Infectious Disease Journal, 2009, 28, 688-692.	2.0	42
18	Epstein-Barr Virus Infection in Transplant Recipients: Sumary of a Workshop on Surveillance, Prevention and Treatment. Canadian Journal of Infectious Diseases & Medical Microbiology, 2002, 13, 89-99.	0.3	41

#	Article	IF	Citations
19	Invasive pneumococcal disease in pediatric organ transplant recipients: A high-risk population. Pediatric Transplantation, 2005, 9, 183-186.	1.0	40
20	Prevention and Treatment of Infectious Complications After Solid Organ Transplantation in Children. Pediatric Clinics of North America, 2010, 57, 459-479.	1.8	37
21	Factors influencing predisposition to sepsis in children with cancers and acquired immunodeficiencies unrelated to human immunodeficiency virus infection. Pediatric Critical Care Medicine, 2005, 6, S80-S86.	0.5	36
22	Risk Factors and Outcomes for Respiratory Syncytial Virus–related Infections in Immunocompromised Children. Pediatric Infectious Disease Journal, 2013, 32, 1073-1076.	2.0	36
23	Varicellaâ€zoster infection in pediatric solidâ€organ transplant recipients:A hospitalâ€based study in the prevaricella vaccine era. Pediatric Transplantation, 2001, 5, 153-159.	1.0	35
24	The Use of Antiviral Drugs for Influenza: Recommended Guidelines for Practitioners. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 273-284.	1.9	34
25	Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatric Transplantation, 2002, 6, 187-192.	1.0	29
26	Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus–associated Deaths in Pediatric Patients in Canada, 2003–2013. Clinical Infectious Diseases, 2019, 68, 113-119.	5.8	26
27	Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 137-146.	0.3	24
28	Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy. Pediatric Transplantation, 2009, 13, 1007-1013.	1.0	20
29	Cow's milk versus soyâ€based formula in mild and moderate diarrhea: a randomized, controlled trial. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 183-187.	1.5	19
30	Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization. American Journal of Transplantation, 2019, 19, 2764-2774.	4.7	19
31	Respiratory syncytial virus infections in pediatric transplant recipients: A Canadian Paediatric Surveillance Program study. Pediatric Transplantation, 2015, 19, 659-662.	1.0	17
32	Immunizations for children with cancer. Pediatric Blood and Cancer, 2007, 49, 1102-1108.	1.5	15
33	Charting the Path Forward: Development, Goals and Initiatives of the 2019 Infectious Diseases Society of America Strategic Plan. Clinical Infectious Diseases, 2019, 69, e1-e7.	5.8	15
34	Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders. Studies in Health Technology and Informatics, 2015, 209, 1-8.	0.3	15
35	The ABC of Epstein-Barr Virus Infections. , 2005, 568, 25-39.		14
36	Clinical consequences of human herpesvirusâ€6 <scp>DNA</scp> emia in peripheral blood in pediatric liver transplant recipients. Pediatric Transplantation, 2014, 18, 47-51.	1.0	14

3

#	Article	IF	Citations
37	Gene expression using microarrays in transplant recipients at risk of EBV lymphoproliferation after organ transplantation: Preliminary proofâ€ofâ€concept. Pediatric Transplantation, 2009, 13, 990-998.	1.0	12
38	The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model. Human Vaccines and Immunotherapeutics, 2017, 13, 599-606.	3.3	12
39	Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE) Tj ETQq1 I	l 0.784314 1.6	1 rgBT /Overl
40	Correlates of Illness Severity in Infectious Mononucleosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 277-280.	1.9	11
41	Fever and respiratory distress in an 8-year-old boy receiving therapy for acute lymphoblastic leukemia. Journal of Pediatrics, 2003, 142, 714-721.	1.8	10
42	Public health implications of MRSA in Canada. Cmaj, 2006, 175, 161-161.	2.0	10
43	Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis. Transplantation, 2018, 102, 1391-1396.	1.0	10
44	Infections among pediatric transplant candidates: An approach to decisionâ€making. Pediatric Transplantation, 2019, 23, e13375.	1.0	10
45	Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients. Transplantation, 2019, 103, e369-e374.	1.0	10
46	SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study. CMAJ Open, 2021, 9, E929-E939.	2.4	10
47	Utility of Head and Neck Biopsies in the Evaluation of Posttransplant Lymphoproliferative Disorder. Otolaryngology - Head and Neck Surgery, 2007, 137, 296-300.	1.9	9
48	Recommended Curriculum for Training in Pediatric Transplant Infectious Diseases. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 4-10.	1.3	8
49	The yield of monitoring for <scp>HSV</scp> and <scp>VZV</scp> viremia in pediatric hematopoietic stem cell transplant patients. Pediatric Transplantation, 2015, 19, 640-644.	1.0	7
50	Guidance for Practitioners on the Use of Antiviral Drugs to Control Influenza Outbreaks in Long-Term Care Facilities in Canada, 2014-2015 Season. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e1-e4.	1.9	7
51	Risk stratification of immunocompromised children, including pediatric transplant recipients at risk of severe respiratory syncytial virus disease. Pediatric Transplantation, 2019, 23, e13336.	1.0	7
52	Management and prevention of varicella and measles infections in pediatric solid organ transplant candidates and recipients: An IPTA survey of current practice. Pediatric Transplantation, 2020, 24, e13830.	1.0	7
53	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	7
54	Care processes and structures associated with higher medication adherence in adolescent and young adult transplant recipients. Pediatric Transplantation, 2021, 25, e14106.	1.0	7

#	Article	IF	CITATIONS
55	Serotypes of respiratory tract isolates of Streptococcus pneumoniae from Jamaican children. International Journal of Infectious Diseases, 2003, 7, 29-34.	3.3	6
56	The genetic diversity of Epstein–Barr virus in the setting of transplantation relative to nonâ€transplant settings: A feasibility study. Pediatric Transplantation, 2016, 20, 124-129.	1.0	5
57	Severe Thrombocytopenia in Sickle Cell Crisis. Pediatric Hematology and Oncology, 1988, 5, 137-141.	0.8	4
58	Community-Acquired Pneumonia in Children: A Multidisciplinary Consensus Review. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 3B-11B.	0.3	4
59	Epstein-Barr Virus Vaccination of Transplant Candidates: Light at the End of the Tunnel?. Transplantation, 2009, 88, 976-977.	1.0	4
60	Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e5-e8.	1.9	4
61	Pediatric transplantation case conference: Update on cytomegalovirus. Pediatric Transplantation, 2018, 22, e13276.	1.0	4
62	Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: A hospitalâ€based analysis. Pediatric Transplantation, 2020, 24, e13650.	1.0	4
63	Solid organ transplant–specific antibiogram in a tertiary pediatric hospital in Canada. Pediatric Transplantation, 2021, 25, e13980.	1.0	4
64	Management of infections in the immunocompromised child: General principles. LymphoSign Journal, 2016, 3, 87-98.	0.2	4
65	Eosinophilic esophagitis after organ transplantation and postâ€transplant lymphoproliferative disorder: More questions than answers. Pediatric Transplantation, 2014, 18, 665-667.	1.0	3
66	Clinical Features and Diagnostic Evaluation of Posttransplant Lymphoproliferative Disorder. , 2010, , 69-88.		3
67	Pediatric Infective Endocarditis Over the Last 30 Years: Thromboembolic Complications and Associations of Valve Vegetation and Heart Failure with Increased Mortality. Blood, 2010, 116, 4223-4223.	1.4	3
68	Acute Rheumatic Fever: Findings of a Hospital-Based Study and an Overview of Reported Outbreaks. Canadian Journal of Infectious Diseases & Medical Microbiology, 1990, 1, 77-81.	0.3	2
69	Prevention of perinatal group B streptococcal disease in Canada: An update. Paediatrics and Child Health, 1997, 2, 319-323.	0.6	2
70	The Battle against Influenza: The Role of Neuraminidase Inhibitors in Children. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 295-298.	0.3	2
71	Enterovirus D68 and disease severity: more questions than answers. Cmaj, 2015, 187, 1269-1270.	2.0	2
72	Epsteinâ€Barr virus latent gene EBNAâ€1 genetic diversity among transplant patients compared with patients with infectious mononucleosis. Clinical Transplantation, 2019, 33, e13504.	1.6	2

#	Article	IF	Citations
73	Post-transplant Lymphoproliferative Disorder in Pediatric Patients: Clinical Sites of Occurrence and Related Survival Rates Open Forum Infectious Diseases, 2016, 3, .	0.9	2
74	BK virus in solid organ transplantation: Pretransplant screening of recipients and risk factors for disease. Pediatric Transplantation, 2017, 21, e12906.	1.0	1
75	Epstein-Barr virus and posttransplant lymphoproliferative disorder. , 2021, , 126-133.e3.		1
76	The significance and impact of SARS oVâ€⊋ variants of concern in pediatric solid organ transplantation: More unknowns than knowns. Pediatric Transplantation, 2021, 25, e14071.	1.0	1
77	Minimizing infection risks after paediatric organ transplants: Advice for practitioners. Paediatrics and Child Health, 2013, 18, 143-54.	0.6	1
78	Medical Decision Analysis in Infectious Diseases. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 317-321.	0.3	0
79	Response to a Protease-Inhibitor (Ritonavir)-Containing Combination Antiretroviral Regimen in HIV-Infected Children. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 89-93.	0.3	0
80	Antiviral Agents, Vaccines, and Immunotherapies. Annals of Internal Medicine, 2005, 142, 686.	3.9	0
81	Commentary on â€~Neuraminidase inhibitors for preventing and treating influenza in children'. Evidence-Based Child Health: A Cochrane Review Journal, 2008, 3, 585-588.	2.0	0
82	Chronic high Epstein–Barr virus load carriage: Do liver transplant recipients fare better than heart recipients?. Pediatric Transplantation, 2009, 13, 268-271.	1.0	0
83	Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study of Respiratory Syncytial Virus-Associated Deaths in Pediatric Patients in Canada: A Retrospective Review From 2003 to 2013. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
84	Prevention and treatment of influenza illness: A seasonal challenge for transplant patients. Pediatric Transplantation, 2017, 21, e12882.	1.0	0
85	657. Epstein–Barr Virus Genetic Diversity in Blood vs. Saliva Samples From Patients with Infectious Mononucleosis. Open Forum Infectious Diseases, 2018, 5, S238-S238.	0.9	0
86	1778. Epstein–Barr Virus Genetic Diversity: Evaluation of BZLF1 Variants among Bone Marrow Transplant Patients and Individuals with Infectious Mononucleosis. Open Forum Infectious Diseases, 2019, 6, S655-S655.	0.9	0
87	Winning with poo? Fecal microbiome transplantation as an emerging strategy for the management of recurrent <i>Clostridioides difficile</i> infection in children. Pediatric Transplantation, 2020, 24, e13651.	1.0	0
88	Clinical Features and Diagnostic Considerations. , 2021, , 129-148.		0
89	Human Metapneumovirus Infection In Children with Cancer. Blood, 2010, 116, 3910-3910.	1.4	0
90	Herpesvirus Viremia and Engraftment Status of Umbilical Cord Blood in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2011, 118, 3021-3021.	1.4	0

#	Article	IF	CITATIONS
91	2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada. Jammi, 2020, 5, 214-222.	0.5	O
92	Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients. Minerva Pediatrica, 2010, 62, 57-69.	2.7	0
93	2021–2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada. Jammi, 2022, 7, 1-7.	0.5	O
94	The challenge of evaluating of <scp>SARS oV</scp> â€2 antibody responses among vaccinated transplant patients. Pediatric Transplantation, 2022, 26, .	1.0	0